The current study findings offer further assurance that DPP-4 inhibitors are safe to be used together with insulin in progressed T2DM patients in terms of infectious disease risks, whereas the link between SGLT-2 inhibitors and genital infection risks was also confirmed in our study. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.